Samil Pharmaceutical Achieves Record First Half Sales of 108.6 Billion Won

Samil Pharmaceutical announced on the 14th that it achieved sales of 108.6 billion KRW and an operating profit of 7.2 billion KRW in the first half of this year on a separate basis, representing growth of 15.3% and 42.8%, respectively, compared to the same period last year.

The increase in sales is attributed to steady growth of existing product lineups such as 'Libact' and 'Lividy', as well as recently launched new products including 'Rebakei', 'Amelibu', and 'Aphilibu'. By business division, all divisions?ETC Sales Headquarters focused on internal medicine, CNS (Central Nervous System) Sales Headquarters, and Ophthalmology Sales Headquarters?showed balanced growth. Among these, Aphilibu, an Eylea biosimilar developed by Samsung Bioepis, recorded a surprising sales figure of 1 billion KRW in its first month after launching in May, and steady growth is expected to continue in the second half of the year.

The CNS division, which has recently been experiencing high growth, also achieved a cumulative half-year performance of 17.3 billion KRW, marking an explosive growth rate of 46.3% compared to the same period last year.

Samil Pharmaceutical’s CNS division recorded sales of 6.7 billion KRW in 2021. However, since the second half of 2021, it has formed a dedicated sales team and continuously expanded new psychiatric drug lineups such as Viatris and Sandoz, resulting in sales of 21.1 billion KRW in 2022 and 28 billion KRW in 2023, maintaining rapid growth.

A company representative stated, “Along with steady growth in our core business, we expect additional growth drivers to be secured when the global ophthalmic solution CMO factory begins full-scale operation starting next year.”